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Figure 2: Statistically significant direct and indirect paths in the model
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Aim
• Investigate the complex relationships between selected socio-demographic and
illness antecedents of cancer patients’
 
symptom experience, following chemotherapy
• Test the relationships between these variables and patients’
 
quality of life outcomes
Methods
Patients
• 219 cancer patients consecutively recruited from outpatient clinics at 2 tertiary hospitals in
Brisbane and interviewed
 
one month after commencing chemotherapy treatment (T1), then
6-monthly, as part of a 2-year longitudinal study
• Mixed diagnoses: breast (29%); haematological
 
(21%); colorectal (20%); other (30%) 
• 64% females; Age: Range 18 to 79 years,  Median = 52 years
• Household income: median group =AUD 40000-49000
• Comorbidities: none (38%); 1 to 4 (62%)
• Chemotherapy toxicity: low (30%); moderate/high (70%)
• Tumour
 
type: solid (21%), haematological
 
(79%)
• Married (49%); Educated/trade qualified (45.6%); Living with someone (87.2%)
• Functionality:  Fully mobile (37%); Immobile/ambulatory (63%)
Background
Symptom experience, quality of life (QOL) and functional status are important outcomes of 
interest in cancer research.  The Theory of Unpleasant Symptoms (TOUS) (Lenz, Suppe
 
et 
al. 1995; Lenz, Pugh et al. 1997) suggests the symptom experience is influenced by 
physiological, situational and psychological factors, and impacts on functionality and quality 
of life outcomes.  
Patient and clinical characteristics influencing social support,
 
symptom distress (Cooley 
2000), physical functioning (Sarna
 
1994), and quality of life include age, gender, income    
and comorbidities.  Key predictors of quality of life and symptom distress in cancer patients 
have been identified variously as chemotherapy treatment, patient’s medical condition, 
social support, and income (Mols, Ingerhoets
 
et al. 2005).  Social support literature 
highlights the complexity of the relationships between social support and patient outcomes.  
Social support has been recognized as being beneficial in helping patients adjust to the 
cancer experience (Flanagan and Holmes 2000).
To date, no path analysis by structural equation modeling (SEM) has been reported to     
collectively investigate predictors and outcomes of cancer patients’
 
symptom experience.  
SEM extends multivariate analyses by allowing for measurement error and providing 
goodness-of-fit statistics of how well the data fit the proposed theoretical
 
model.
Concept Instrument Scoring
Social support Social Support Questionnaire for Transactions 
(SSQT) -
 
incorporates emotional and 
instrumental social support -
 
23 items
(Suurmeijer, Doeglas
 
et al. 1995)
High total mean scores = more
social support.
(1=seldom/never, 4=often)
Physical symptom 
experience
Rotterdam Symptom Checklist, 43 symptoms 
(de Haes, van Knippenberg
 
et al. 1990)
High total mean scores = more
distress
(1=no bother, 4=very much)
Cancer-related 
Quality of life
Patient wellbeing
Cancer Rehabilitation Evaluation System 
Short Form (CARES-SF) -
 
reflects problems 
and  rehabilitation needs (Schag, Ganz
 
et al. 
1991) –
 
59 items
Life Satisfaction Scale  –
 
general satisfaction   
with aspects of  normal life (Clinton, Lunney
 
et 
al. 1998) -
 
7 items
High total mean scores = better QOL
(1=very dissatisfied, 5=very satisfied)
High total mean scores = worse QOL
(0=no problem at all, 4=very much)
Physical 
functionality
• European Cooperative Oncology Group 
( ECOG)
 
–
 
1 item
1= Fully mobile  0=Ambulatory/immobile
Table 1: Instruments
Figure 1:  Relationships in the symptom experience model, based on TOUS
Results 
• 14 of 37 path coefficients (Figure 2) had significant t-values (p<.05), ranging from
0.14 (weak) to 0.50 (moderate).
• Model found to be an adequate fit to the data. [Chi-square χ2 (3) =2.9,  p>.05;
RMSEA 90%, CI = (0.0, 0.11), GFI = .998, CFI = 1.0] 
• Significant correlations between demographic and illness variables ranged from  0.14 
to 0.32 (weak to moderate).  
Outcome (Range)              Mean (95% CI)       Outcome (Range) Mean (95% CI)
Social support (1-4)            2.8 (2.7, 2.9)          Symptom Exp.(1-4)     1.28 (1.25, 1.31)
Cancer-related QOL(0-4)    0.67(.61, .72)         Wellbeing (1-5)             3.95 (3.9, 4.0)
Symptom experience
• Symptom experience more distressing for younger, low income, and female patients.
Cancer-related quality of life
• Older patients experienced fewer problems affecting their QOL
• Patients with solid tumours
 
experienced a poorer QOL compared to those with
haematological
 
tumours
Patient wellbeing
• Younger and female patients were more likely to utilize social
 
support and
increased social support was associated with improved wellbeing
• Indication that increasing toxicity was associated with improved wellbeing is not
readily explained and requires further investigation. 
Proportion of the variance explained in the model (R2)
• 16% of social support;  16% of the symptom experience; 10% of physical 
functionality; 36% of cancer-related quality of life; 34% of patients’
 
wellbeing
Analysis
• Secondary analysis of patient data at T1
• Structural Equation modeling (SEM) using AMOS (v6);  maximum likelihood estimation
tested the hypothesised
 
relationships in Figure 1, based on TOUS 
• Model Fit assessed by the following “goodness-of-fit”
 
statistics:
• Chi-square (χ2),  p>.05 indicates no difference;
• Goodness of Fit Index (GFI) >0.95;
• Root Mean Square Error of Approximation (RMSEA) <0.08
• Comparative Fit Index (CFI) >0.95, comparing hypothesised
 
model to null model 
• The relative importance of variables based on standardized regression coefficients (β)
• Statistical significance determined by 95% confidence intervals 
• Regression coefficients  ≥
 
0.25 considered practically significant
• Model validated by examination of the individual parameter estimates in terms
of statistical significance, the predicted direction, and being non-trivial.
Conclusion
• The proposed model fits the data and supports the TOUS in which socio-demographic
and illness variables are predictors of QOL, both directly and indirectly through the
symptom experience  
• Symptom experience is the most relevant variable in the model predicting patients’
cancer-related quality of life and wellbeing 
• Age is an important factor
• Social support directly effects patients’
 
wellbeing but was not a mediator in the
relationship between age, gender, income and the symptom experience
Limitations
• Anxiety and depression were not measured in the study;
• Global scores used in this path model.; use of latent variables and a measurement model
in SEM would account for measurement error.
Clinical implications
• Further understanding of the symptom experience by consideration of: 
(1) the effects of age on the symptom experience and quality of life outcomes:
-
 
being older was associated with reduced mobility; 
-
 
being younger was associated with more symptom distress
(2) a more distressing symptom experience was associated with
 
poor quality of life
(3) improved social support for older patients with potential
 
to improve overall quality of life
